The purpose of this trial is to assess whether the blood pressure lowering agent candesartan
(an angiotensin receptor type 1 blocker) is effective when given to patients with acute
stroke and elevated blood pressure.
Hypothesis:
AT1 receptor blockade with candesartan in acute stroke will:
1. reduce the risk of death or major disability at 6 months by a 6% absolute risk
reduction, relative to placebo.
2. reduce the risk of the combined event of "vascular" death, myocardial infarction, or
stroke during the first 6 months by a 25% relative risk reduction, relative to placebo
Phase:
Phase 3
Details
Lead Sponsor:
Ullevaal University Hospital
Collaborators:
AstraZeneca Southern-Eastern Norway Health Authorities RHF Takeda